Top Markets
Coin of the day
Neovacs S.A. Neovacs S.A.

Neovacs S.A.

ALNEV
Rang in Aktien #21228
Neovacs S.A., a biotechnology company, focuses on the development of... Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.
Aktienkurs
$0.00047446
Marktkapitalisierung
$82.80
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
-98.16%
Land
FR
Handel Neovacs S.A. (ALNEV)

Kategorie

EPS für Neovacs S.A. (ALNEV)
EPS zum December 2024 TTM: $-34.55K
Laut den aktuellen Finanzberichten und dem Aktienkurs von Neovacs S.A. beträgt das aktuelle EPS des Unternehmens (TTM) $-34.55K. Am Ende des Jahres 2023 betrug das EPS $-275.26K eine Steigerung gegenüber dem EPS von 2022, das $-1.26 betrug.
EPS-Verlauf von Neovacs S.A. von 2007 bis 2026
EPS am Ende jedes Jahres
Jahr EPS ändert
2026 (TTM) $-34.55K 17,504.17%
2024 $-196.26 -99.93%
2023 $-275.26K 21,820,011.06%
2022 $-1.26 -100.00%
2021 $-5.367T -93.96%
2020 $-88.856T -79.32%
2019 $-429.767T -54.85%
2018 $-951.868T -52.78%
2017 $-2.02Qa -24.26%
2016 $-2.66Qa 115.81%
2015 $-1.23Qa -59.95%
2014 $-3.08Qa -17.40%
2013 $-3.73Qa -18.52%
2012 $-4.58Qa -9.86%
2011 $-5.08Qa -27.43%
2010 $-6.99Qa 21.97%
2009 $-5.73Qa 53.05%
2008 $-3.75Qa -7.11%
2007 $-4.03Qa 0.00%
EPS für ähnliche Unternehmen oder Wettbewerber
Unternehmen EPS EPS-Differenz Land
$3.62 -100.01%
DK
$15.47 -100.04%
US
$43.12 -100.12%
US
$9.62 -100.03%
BE
$38.32 -100.11%
NL